vs

Side-by-side financial comparison of ACACIA RESEARCH CORP (ACTG) and ImmunityBio, Inc. (IBRX). Click either name above to swap in a different company.

ACACIA RESEARCH CORP is the larger business by last-quarter revenue ($50.1M vs $38.3M, roughly 1.3× ImmunityBio, Inc.). ACACIA RESEARCH CORP runs the higher net margin — 6.8% vs -161.8%, a 168.6% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 2.6%).

Acacia Research Corporation is a publicly traded American company based in New York City. It acquires and operates businesses in industries including the technology, energy, and industrial/manufacturing sectors. Acacia has a strategic relationship with Starboard Value, LP, the company's controlling shareholder. The company has been characterized as a patent troll.

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.

ACTG vs IBRX — Head-to-Head

Bigger by revenue
ACTG
ACTG
1.3× larger
ACTG
$50.1M
$38.3M
IBRX
Growing faster (revenue YoY)
IBRX
IBRX
+404.3% gap
IBRX
407.0%
2.6%
ACTG
Higher net margin
ACTG
ACTG
168.6% more per $
ACTG
6.8%
-161.8%
IBRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ACTG
ACTG
IBRX
IBRX
Revenue
$50.1M
$38.3M
Net Profit
$3.4M
$-61.9M
Gross Margin
12.8%
99.0%
Operating Margin
-26.1%
-169.0%
Net Margin
6.8%
-161.8%
Revenue YoY
2.6%
407.0%
Net Profit YoY
125.5%
-4.7%
EPS (diluted)
$0.03
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACTG
ACTG
IBRX
IBRX
Q4 25
$50.1M
$38.3M
Q3 25
$59.4M
$32.1M
Q2 25
$51.2M
$26.4M
Q1 25
$124.4M
$16.5M
Q4 24
$48.8M
$7.6M
Q3 24
$23.3M
$6.1M
Q2 24
$25.8M
Q1 24
$24.3M
Net Profit
ACTG
ACTG
IBRX
IBRX
Q4 25
$3.4M
$-61.9M
Q3 25
$-2.7M
$-67.3M
Q2 25
$-3.3M
$-92.6M
Q1 25
$24.3M
$-129.6M
Q4 24
$-13.4M
$-59.2M
Q3 24
$-14.0M
$-85.7M
Q2 24
$-8.4M
Q1 24
$-186.0K
Gross Margin
ACTG
ACTG
IBRX
IBRX
Q4 25
12.8%
99.0%
Q3 25
21.2%
99.4%
Q2 25
12.8%
99.5%
Q1 25
47.4%
99.6%
Q4 24
17.6%
Q3 24
10.1%
Q2 24
26.2%
Q1 24
49.2%
Operating Margin
ACTG
ACTG
IBRX
IBRX
Q4 25
-26.1%
-169.0%
Q3 25
-10.8%
-173.5%
Q2 25
-24.2%
-269.8%
Q1 25
30.8%
-390.1%
Q4 24
-32.4%
-919.0%
Q3 24
-44.1%
-1314.3%
Q2 24
-18.4%
Q1 24
-8.6%
Net Margin
ACTG
ACTG
IBRX
IBRX
Q4 25
6.8%
-161.8%
Q3 25
-4.6%
-209.8%
Q2 25
-6.4%
-350.3%
Q1 25
19.5%
-784.9%
Q4 24
-27.5%
-783.4%
Q3 24
-60.0%
-1404.0%
Q2 24
-32.7%
Q1 24
-0.8%
EPS (diluted)
ACTG
ACTG
IBRX
IBRX
Q4 25
$0.03
$-0.06
Q3 25
$-0.03
$-0.07
Q2 25
$-0.03
$-0.10
Q1 25
$0.25
$-0.15
Q4 24
$-0.14
$-0.08
Q3 24
$-0.14
$-0.14
Q2 24
$-0.08
Q1 24
$0.00

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACTG
ACTG
IBRX
IBRX
Cash + ST InvestmentsLiquidity on hand
$306.7M
$242.8M
Total DebtLower is stronger
$91.9M
Stockholders' EquityBook value
$543.5M
$-500.5M
Total Assets
$771.0M
$501.9M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACTG
ACTG
IBRX
IBRX
Q4 25
$306.7M
$242.8M
Q3 25
$301.8M
$257.8M
Q2 25
$316.7M
$153.7M
Q1 25
$272.0M
$61.6M
Q4 24
$273.9M
$149.8M
Q3 24
$410.9M
$130.4M
Q2 24
$441.9M
Q1 24
$498.4M
Total Debt
ACTG
ACTG
IBRX
IBRX
Q4 25
$91.9M
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ACTG
ACTG
IBRX
IBRX
Q4 25
$543.5M
$-500.5M
Q3 25
$537.6M
$-524.3M
Q2 25
$538.6M
$-570.7M
Q1 25
$540.2M
$-591.4M
Q4 24
$514.8M
$-489.1M
Q3 24
$540.2M
$-745.1M
Q2 24
$560.7M
Q1 24
$568.3M
Total Assets
ACTG
ACTG
IBRX
IBRX
Q4 25
$771.0M
$501.9M
Q3 25
$768.9M
$519.0M
Q2 25
$775.5M
$402.1M
Q1 25
$801.6M
$303.8M
Q4 24
$756.4M
$382.9M
Q3 24
$707.6M
$364.6M
Q2 24
$753.6M
Q1 24
$631.7M
Debt / Equity
ACTG
ACTG
IBRX
IBRX
Q4 25
0.17×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACTG
ACTG
IBRX
IBRX
Operating Cash FlowLast quarter
$75.2M
$-70.4M
Free Cash FlowOCF − Capex
$-71.3M
FCF MarginFCF / Revenue
-186.2%
Capex IntensityCapex / Revenue
2.4%
Cash ConversionOCF / Net Profit
22.01×
TTM Free Cash FlowTrailing 4 quarters
$-308.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACTG
ACTG
IBRX
IBRX
Q4 25
$75.2M
$-70.4M
Q3 25
$9.5M
$-68.9M
Q2 25
$50.1M
$-79.7M
Q1 25
$2.4M
$-85.9M
Q4 24
$50.1M
$-85.1M
Q3 24
$-593.0K
$-98.8M
Q2 24
$16.1M
Q1 24
$54.8M
Free Cash Flow
ACTG
ACTG
IBRX
IBRX
Q4 25
$-71.3M
Q3 25
$-69.6M
Q2 25
$-80.8M
Q1 25
$335.0K
$-87.0M
Q4 24
$-98.5M
$-87.3M
Q3 24
$-2.8M
$-101.6M
Q2 24
$-126.7M
Q1 24
$54.6M
FCF Margin
ACTG
ACTG
IBRX
IBRX
Q4 25
-186.2%
Q3 25
-217.2%
Q2 25
-305.9%
Q1 25
0.3%
-526.9%
Q4 24
-201.8%
-1155.4%
Q3 24
-12.1%
-1663.2%
Q2 24
-490.5%
Q1 24
224.4%
Capex Intensity
ACTG
ACTG
IBRX
IBRX
Q4 25
2.4%
Q3 25
2.3%
Q2 25
4.1%
Q1 25
1.7%
6.8%
Q4 24
304.4%
28.0%
Q3 24
9.6%
45.7%
Q2 24
553.0%
Q1 24
1.1%
Cash Conversion
ACTG
ACTG
IBRX
IBRX
Q4 25
22.01×
Q3 25
Q2 25
Q1 25
0.10×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACTG
ACTG

Energy Operations$16.0M32%
Transportation Safety$10.4M21%
Office Storage And Display Solutions$8.4M17%
Printers Consumables And Parts$6.5M13%
Natural Gas Reserves$5.1M10%
Natural Gas Liquids Reserves$3.3M7%

IBRX
IBRX

Segment breakdown not available.

Related Comparisons